Current therapeutic landscape for small-cell lung cancer

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the current therapeutic landscape for small-cell lung cancer (SCLC), including the epidemiology and mortality rates, likely causes, and current treatment options. First-line standard of care (SOC) is anti-PD-L1 immunotherapy combined with chemotherapy, with second-line SOC including topotecan. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.